Ann: 2024 Half Year Announcement, page-6

Nice that they got some Penthrox revenue growth from price increases, but that’s the only positive I see. Conversely, no doubts costs are rising too so hardly a big win.

Respiratory very poor.

Auditors now raising concern around going concern which says they are on a runway to running out of cash. So something has to give here. Not sure how they’d raise at current price levels, but what are they raising for? They’ve previously raised for EU expansion, Selfie (where the hell is that at), so can’t keep flogging the same old story.

indicated they’ve undergone some restructuring to cut cost, but its revenue needed here. Not sure a partner is jumping at the France opportunity unless they get most of the margin. Bemusing how they’ve botched this important market ever since it launched, but want shareholders to believe the US will go swimmingly